medicines evaluation board
Responsibility for assessing, authorising and for monitoring the safety of human medicinal products lies with a Board consisting of doctors, pharmacists and scientists. This Medicines Evaluation Board (MEB) has autonomous powers to take decisions on the availability of these medicinal products. The MEB is responsible for authorising and monitoring safe and effective medicinal products on the Dutch market and shares responsibility for authorising medicinal products throughout the European Union.
The MEB consists of a chairman and at least nine to a maximum of seventeen other members (doctors, pharmacists and scientists). The chairman and members are appointed by the Minister for Health, Welfare and Sport.
The chairman and members are appointed for a four-year term and can be reappointed for a further four years. The MEB’s operating modalities and responsibilities are laid down in the Dutch Medicines Act (Geneesmiddelenwet).
You can find agendas and minutes of MEB meetings on the News page in the Human Medicines section.
For more information about a particular MEB member, please click on the name. This will give you more details about the particular member along with a short CV and declaration of interests.
Mandated and authorised officers
The MEB has appointed and mandated officers, who can decide on behalf of the MEB and are authorised to represent the MEB. Furthermore, the MEB has appointed and authorised officers to perform acts on behalf of the MEB with respect to marketing authorisation applications and other procedures.
Go back »